In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AMAG Pharmaceuticals: Enough Irons In The Fire?

Executive Summary

Demand for AMAG’s newly launched Feraheme has been robust but a changing reimbursement climate, especially in the dialysis market, complicates the product’s pricing strategy, and puts increased pressure on management to diversify via dealmaking.
Advertisement

Related Content

Rockwell Sees Opportunity For Triferic In Cost-Sensitive CKD Market
A New Course For AMAG: Expanding Feraheme And Moving Beyond Iron
Your First Drug's Approved and Launched...Now What?
The Rise Of Japanese Pharma Dealmakers
AMAG Pharmaceuticals Irons Out Ex-US Deal With Takeda For Feraheme
Watson Is Bullish On Launching Enhanced Ferrlecit Generic Soon
The Rebirth of A Niche Product: Three Silver Linings on the ESA REMS
Living in a Bipolar World: Implications of the EPO Safety Debate (Part 1)
NitroMed's BiDil Pricing: Test for a Whole Class of New Companies
NitroMed's BiDil Pricing: Test for a Whole Class of New Companies

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003486

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel